Abstract |
The senescence accelerated prone mouse strain 8 (SAMP8) develops age-related deficits in learning and memory. Effects of the azaindolizinone derivative ZSET1446/ST101, a newly synthesized cognitive enhancer, on cognitive impairment and deposition of amyloid β (Aβ) were assessed in the SAMP8. ZSET1446 was administered in drinking water at estimated doses of 0.002, 0.01, and 0.1 mg/kg per day from the age of 8 months. The SAMP8 at the age of 8 months showed cognitive impairment in a novel object recognition task compared with young SAMP8 at the age of 8 weeks. Further, grading scores were gradually increased from 9 to 12 months and Aβ-like immunoreactivity in the hippocampus was increased at the age of 10 months. ZSET1446 ameliorated cognitive deficits of SAMP8 after 4, 8, 12, and 16 weeks of treatment in a novel object recognition test. ZSET1446 also reduced grading scores of SAMP8 after 16 weeks of treatment. Further, 8-week treatment of ZSET1446 significantly reduced the total number of Aβ-positive granules in the hippocampus. These results suggest that ZSET1446 shows ameliorating effects on SAMP8 partly due to the suppression of an increase of Aβ-deposition in the hippocampus.
|
Authors | Yoshimasa Yamaguchi, Kenichi Saito, Toshiyuki Matsuno, Kentaro Takeda, Masataka Hino |
Journal | Journal of pharmacological sciences
(J Pharmacol Sci)
Vol. 119
Issue 2
Pg. 160-6
( 2012)
ISSN: 1347-8648 [Electronic] Japan |
PMID | 22790316
(Publication Type: Journal Article)
|
Chemical References |
- Amyloid beta-Peptides
- Indans
- Neuroprotective Agents
- Spiro Compounds
- spiro(imidazo-(1,2-a)pyridine-3,2-indan)-2(3H)-one
|
Topics |
- Aging
(physiology)
- Alzheimer Disease
- Amyloid beta-Peptides
(metabolism)
- Animals
- Cognition Disorders
(drug therapy, physiopathology)
- Hippocampus
(drug effects, physiology)
- Indans
(pharmacology, therapeutic use)
- Male
- Mice
- Neuroprotective Agents
(pharmacology, therapeutic use)
- Spiro Compounds
(pharmacology, therapeutic use)
|